What is Augie’s Quest?

Under the banner MDA’s Augie’s Quest, Nieto and his wife, Lynne, are supporting MDA’s aggressive fundraising and research effort aimed at finding more effective treatments and, ultimately, a cure for ALS.

How are MDA and Augie’s Quest connected?

MDA’s ALS Division is the world leader among voluntary agencies in fighting ALS, offering the most comprehensive range of services, including a national network of clinics. MDA has dedicated more than $290 million to ALS research, services and education. MDA’s Augie’s Quest is solely dedicated to funding ALS research. Augie’s Quest has raised more than $28 million in less than six years, and 100 percent of all donations to MDA’s Augie’s Quest go directly to research.

Who is Augie Nieto?

A pioneer in the fitness industry, Augie Nieto received a diagnosis of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) in March 2005 and began the fight of his life. Augie was co-founder and president of Life Fitness, and is now chairman of Octane Fitness. As co-chairs of MDA’s ALS Division for the sixth year, the Nietos are raising awareness of the disease through public appearances, speaking engagements, media interviews and public service announcements. For every year since 2006, Augie and Lynne have shared their story on the national broadcast of the MDA Labor Day Telethon. Augie also serves MDA as a national vice president.

What has Augie’s Quest accomplished in its first five years?

Augie’s Quest has funded several successful ALS research projects that have accelerated the development of therapeutics in this disease. Foremost among these is the partnership between MDA’s Augie’s Quest and the ALS Therapy Development Institute (ALS TDI). Thanks to the funds donated by public support of Augie’s Quest (over $22 million to date, matched by ALS TDI for a total investment of more than $44 million), scientists at ALS TDI have screened more than 100 molecules to see if they affect the progression of ALS.

As part of this research, ALS TDI published a seminal paper explaining how to best test potential therapeutics for ALS in animals, and explaining the reason for so many drug development failures to date in ALS. ALS TDI has identified a molecule that significantly increases survival, delays progression and improves body weight in the ALS animal model, and other possibilities are still under investigation. ALS TDI’s CEO and Chief Scientific Officer Steve Perrin is working to bring this first lead molecule to clinical trials.

In addition, MDA’s Augie’s Quest also funded a research project with the Translational Genomics Research Institute in 2006 and donated the seed money for the MDA/ALS Center at UC Irvine in 2007.